Medtronic to Buy SPR Therapeutics for About $650M

Medtronic to pay $650M for Cleveland pain therapy company

The Cleveland company developed a 60-day peripheral nerve stimulation treatment. More than 71% of patients reported significant pain relief.

Medtronic to buy SPR Therapeutics for about $650M

Medtronic would gain a treatment for chronic pain management in its third major acquisition this year.

Medtronic to acquire SPR Therapeutics for $650m

Medtronic is set to acquire SPR Therapeutics for an upfront cash payment of nearly $650m, expanding care options for individuals with chronic pain.The post Medtronic to acquire SPR Therapeutics for $650m appeared first on Medical Device Network.

Medtronic to buy SPR Therapeutics for ~$650 million - BioTuesdays

Medtronic (NYSE: MDT) announced its intent to acquire SPR Therapeutics, a closely held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. Raymond James served as exclusive financial advisor to SPR Therapeutics. The transaction consists of an upfront cash payment of approximately $650 million for all of the outstanding equity in SPR. Chronic pain …